v3.26.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Revenues    
Revenues $ 456,021 $ 615,873
Cost of revenues 54,422 93,296
Cost of revenues - related party 151,213 142,613
Gross profit 250,386 379,964
Operating expenses    
General and administrative expenses 3,756,373 3,000,571
Salary and benefits 1,348,051 1,063,781
Advertising and marketing 822,860 1,478,663
Investor relations 1,561,206 453,749
Stock based compensation 10,794,245 2,355,193
Total operating expenses 18,282,735 8,351,957
Loss from operations (18,032,349) (7,971,993)
Other (income) expense    
Interest expense 103,513 13,700
Amortization of intangible assets 1,122,639 721,533
Impairment of license agreement 1,239,942  
Loss from settlement 125,624
Loss from debt extinguishment - related parties 19,388
Total other (income) expense 2,611,106 735,233
Loss before income taxes (20,643,455) (8,707,226)
Income taxes
Net loss (20,643,455) (8,707,226)
Net loss attributed to non-controlling interest (461) (1,081)
Net loss attributed to Mangoceuticals, Inc. $ (20,642,994) $ (8,706,145)
Basic and diluted loss per share    
Basic loss per share $ (2.17) $ (4.80)
Diluted loss per share $ (2.17) $ (4.80)
Weighted average number of shares outstanding    
Basic 10,071,609 1,978,966
Diluted 10,071,609 1,978,966
Preferred stock dividend requirements $ 1,176,000 $ 802,109
Net loss attributed to Mangoceuticals, Inc. common stockholders $ (21,818,994) $ (9,508,254)